I am a veterinary medical oncologist with a special interest in molecular oncology and a long-term career goal of establishing an independent research program in cancer genetics. My research has focused on determining roles for the essential DNA damage checkpoint protein Hus1 in tumor suppression and physiological DNA damage responses. I have also worked collaboratively with the Webb Laboratory in the School of Applied and Engineering Physics to develop multiphoton microscopy as a diagnostic tool for lung cancer. Ultimately, I want to determine how the genetics of a given tumor can be used to best manipulate therapeutic combinations. I want to evaluate how targeting different signaling pathways within neoplastic cells, including DNA damage response pathways, can be combined with traditional cytotoxic therapies in order to increase the responsiveness of solid tumors. I aim to interact with scientists at all levels of cancer biology, so that clinicians are able to make better use of molecular data as they evaluate treatment strategies and benchtop scientists gain a better understanding of the clinical scenarios driving their questions. In addition to my research goals, I want to continue training undergraduate students, graduate students, and oncology residents in the principles and practice of both clinical and molecular oncology.
Dr. Hume received her DVM, Cum Laude, in 2003 from Auburn University and received her Board Certification in Veterinary Internal Medicine, Specialty of Oncology, in 2008. She completed her three-year residency at North Carolina State University prior to receiving one of the first Cornell Clinical Fellows awards made in 2008.
Dr. Hume’s long term goals are to interact with clinician and basic scientists at all levels of cancer biology, recognizing the need to marry the two vital tracks. Mentoring and teaching undergraduate students, graduate students, and oncology residents in both clinical and molecular oncology is one of Dr. Hume’s overarching career goals.